Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
Authors:
Open Access
- 26 May 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 899272
Abstract
Virtually all patients with multiple myeloma become unresponsive to treatment with proteasome inhibitors over time. Relapsed/refractory multiple myeloma is accompanied by the clonal evolution of myeloma cells with heterogeneous genomic aberrations, diverse proteomic and metabolic alterations, and profound changes of the bone marrow microenvironment. However, the molecular mechanisms that drive resistance to proteasome inhibitors within the context of the bone marrow microenvironment remain elusive. In this review article, we summarize the latest knowledge about the complex interaction of malignant plasma cells with its surrounding microenvironment. We discuss the pivotal role of metabolic reprograming of malignant plasma cells within the tumor microenvironment with a subsequent focus on metabolic rewiring in plasma cells upon treatment with proteasome inhibitors, driving multiple ways of adaptation to the treatment. At the same time, mutual interaction of plasma cells with the surrounding tumor microenvironment drives multiple metabolic alterations in the bone marrow. This provides a tumor-promoting environment, but at the same time may offer novel therapeutic options for the treatment of relapsed/refractory myeloma patients.Keywords
Funding Information
- Krebsliga Schweiz
This publication has 344 references indexed in Scilit:
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balanceBlood Cancer Journal, 2013
- Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome InhibitionMolecular Cell, 2012
- Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B CellsCell Metabolism, 2012
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myelomaLeukemia, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Diverse evolutionary paths to cell adhesionTrends in Cell Biology, 2010
- Oxidative stress and glutathione in TGF-β-mediated fibrogenesisFree Radical Biology and Medicine, 2010
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic TargetCancer Cell, 2009
- Glutathione: Overview of its protective roles, measurement, and biosynthesisMolecular Aspects of Medicine, 2009
- Regulation of glutathione synthesisMolecular Aspects of Medicine, 2009